Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	MDPI AG 2022-05-01
Seri Bilgileri:	Vaccines
Konular:	pneumococcal vaccination immunocompromised host transplant recipient autoimmune disease vaccine immunogenicity
Online Erişim:	https://www.mdpi.com/2076-393X/10/5/795
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!